Mechanistically, Jin et al. reported that the response of liver cancer to lenvatinib is limited by epithelial growth factor receptor (EGFR) activation, and that integrative therapy with the EGFR inhibitor, gefitinib, alongside lenvatinib may be of potential value for the approximately 50% of patients with advanced HCC who have high levels of EGFR [10]. This evidence concerns the gene EGFR and hepatocellular carcinoma.